RESMED DRC 2026 Q2
Earnings Overview & AI Insights

Earnings Performance

Summary of Financial Performance: ResMed delivered strong Q4 FY2026 results with revenue of $1.5 billion, up 9% headline and 8% constant-currency. Non-GAAP EPS rose 16% to $2.95. Full-year FY2026 revenue grew 10% headline/8% constant-currency, non-GAAP EPS grew 17%, gross margin expanded 290 bps for the year, and free cash flow reached $1.6 billion. Q4 gross margin was 62.3% (+90 bps YoY) and operating margin was 35.2%. Cash ended at about $1.5 billion.

Company Outlook & Strategy: Management emphasized three FY2027 priorities: operational and innovation excellence, active portfolio management, and strong capital returns. FY2027 guidance calls for 5%-7% core constant-currency revenue growth and non-GAAP EPS of $12.00-$12.25, with low-double-digit gross margin expansion and slight operating margin improvement. Reported revenue is expected at $5.75-$5.85 billion. ResMed plans to increase transparency with more revenue disclosure and annual guidance. Capital returns are set to accelerate, with over $1.85 billion expected to be returned through dividends and buybacks, including a $450 million ASR. The company also raised its quarterly dividend by 10% to $0.66/share.

Key Industry Trends: Management highlighted rising sleep-health awareness, driven by wearables, consumer interest, and GLP-1 adoption. ResMed believes GLP-1s are a tailwind because patients using both GLP-1s and PAP therapy show higher initiation and resupply rates. Wearable partnerships, especially with Oura, are helping create earlier diagnosis and treatment pathways. Broader demographic shifts, including more women and younger patients in the pipeline, are influencing product design, education, and marketing.

Operational Highlights: ResMed continued global rollout of AirSense 11, expanded AirCurve 11 ST/ST-A in the U.S. and several international markets, and launched new fabric masks such as AirTouch N30i, AirTouch F30i, and AirFit F40. The GenAI digital sleep coach in MyAir surpassed 1.5 million inquiries and reduced customer service demand. The Noctrix acquisition closed June 1 and is being integrated, while MatrixCare divestiture was announced and is expected to close around September 1, 2026. FY2027 capex is expected to rise to $160 million-$180 million to expand and automate manufacturing. The Astral field safety corrective action remains a major operational focus, with resources redirected to patient support and corrective activities.

Challenges & Risks: Key risks include the Astral field safety notice, which reduces FY2027 revenue by about 130 bps or $75 million and drove a $42 million Q4 provision. Management also cited macro uncertainty, inflation in electronics and freight, FX headwinds, and earnings dilution from Noctrix and MatrixCare. Life support device revenue declined sharply in Q4 across regions, reflecting the Astral-related impact. Management noted the need to manage stranded costs from the MatrixCare divestiture and to maintain supply chain efficiency amid inflation.

Key Analyst Questions & Responses: The main Q&A topic shown was gross margin sequential movement and pricing. Management responded that global inflation, especially in fuel and freight, is affecting costs across 140 countries, even as ResMed is raising prices where appropriate. The company reiterated that productivity gains, supply-chain efficiencies, and modest strategic price increases are expected to offset much of the inflationary pressure and support margin expansion over time.